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The purine analogs, ﬂudarabine nucleoside (FdA), and cladribine (CdA) (1μM, 24 hours), signiﬁcantly changed the levels of
some surface antigens on the human B-cell lines MEC2 and Raji. Changes in the surface proteins were identiﬁed using a Cluster
of Diﬀerentiation (CD) antibody microarray that captures live cells and conﬁrmed by ﬂow cytometry. For Raji cells, CdA up-
regulated CD10, CD54, CD80, and CD86, with repression of CD22, while FdA up-regulated CD20, CD54, CD80, CD86 and
CD95. For MEC2 cells, CdA up-regulated CD11a, CD20, CD43, CD45, CD52, CD54, CD62L, CD80, CD86, and CD95, but FdA
had no eﬀect. Up-regulation of particular CD antigens induced on a B-cell lymphoproliferative disorder by a purine analog could
provide targets for therapeutic antibodies with synergistic cell killing.
1.Introduction
Purine nucleoside analogs are eﬀective in the treatment
of some B-lymphoproliferative disorders (B-LPDs). Flu-
darabine (FdAMP, 9-β-D-arabinofuranosyl-2-ﬂuoroadenine
5 -monophosphate) induces cell cycle arrest and apop-
tosis [1] and is used to treat patients with chronic
lymphocytic leukemia (CLL) and indolent non-Hodgkins
lymphoma (NHL) [2–4]. Cladribine (CdA, 2-chloro-2 -
deoxyadenosine) is eﬀective against CLL, low-grade NHL,
and hairy cell leukemia (HCL) [5]. FdAMP is adminis-
tered as the nucleoside 5 -monophosphate derivative and is
hydrolyzed outside the cell to ﬂudarabine nucleoside (FdA)
then transported and phosphorylated inside the cell (FdA
→ FdAMP → FdADP → FdATP). CdA is administered as
the nucleoside derivative and converted to the triphosphate
(CdATP). FdATP and CdATP both inhibit ribonucleotide
reductase, and at higher concentrations they inhibit DNA
and RNA synthesis [3, 6] and induce apoptosis [7]. The
main side-eﬀect of these purine analogs is myelosuppression
leading to opportunistic infections [8, 9].
Cell surface molecules are classiﬁed as Cluster of Dif-
ferentiation (CD) antigens (Human Cell Diﬀerentiation
Molecules-HCDMs, http://www.hlda8.org/)a n dh a v eav a r i -
ety of functions such as cytokine and growth factor recep-
tors, transporters, ion channels, cell-cell interactions, and
adhesion molecules [10]. CD antigens are potential targets
for treatment of B-LPD with therapeutic antibodies. For
example, antibodies against CD20 (rituximab, Mabthera),
CD52 (alemtuzumab, Campath-1H), and CD80 (galiximab)
are eﬀective for treatment of some B-LPDs such as CLL and
NHL [11, 12]. Immunotoxins such as BL22 directed against
CD22 may be useful in the treatment of CLL, NHL and HCL
[13]. Radioimmunoconjugates, such as 131I-tositumomab
(Bexxar) and 90Y-ibritumomab tiuxetan (Zevalin), directed
against CD20 are eﬀective for treatment of NHL [14].
Recent clinical trials support combination of a purine
nucleoside analog with a therapeutic antibody for treat-
ment of CLL and NHL [3]. Combination therapy with
rituximab and FdAMP prolongs progression-free survival
of patients with previously untreated CLL [15]. FdAMP,
cyclophosphamide, and rituximab (FCR) produce a high
rate of complete remissions in untreated CLL [16]. FdAMP
and alemtuzumab are active against CLL that is refrac-
tory to either drug alone [17]. The combination of CdA
with rituximab is also eﬀective against CLL and indolent2 International Journal of Proteomics
lymphoma [18]. These results indicate synergy between
purine analogs and therapeutic antibodies.
Antibody microarray technology is a powerful tool in
proteomics, target discovery, and diﬀerential analysis. A CD
antibodymicroarray(DotScanTM)hasbeendev elopedinour
laboratory that enables extensive surface proﬁles of leuko-
cytes to be obtained in a single, simple assay. DotScanTM
has been used to determine immunophenotypic changes on
human HL60 leukemia cells during diﬀerentiation [19, 20].
In the present work, we have used the microarray to identify
CD antigens whose levels change on the human B-lymphoid
cell lines MEC2 (derived from CLL) and Raji (from Burkitt’s
lymphoma) treated with CdA or FdA, with subsequent
quantitative analysis of those antigens by ﬂow cytometry.
The results show that CdA (1μM, 24 hours) changes the
surface protein proﬁles of MEC2 and Raji cells and FdA
(1μM, 24 hours) changes the proﬁle of Raji but not MEC2.
Up-regulation of particular CD antigens induced on a B-
LPD by a purine analog could provide targets for combined
treatment with purine analogs and therapeutic antibodies,
directing cytotoxic activity speciﬁcally against the neoplastic
cells.
2.MaterialsandMethods
2.1. Reagents. RPMI 1640 medium (Hepes modiﬁcation),
FdA, and Trypan blue were purchased from Sigma Aldrich
(Castle Hill, Australia). CdA was a kind of gift from the
National Cancer Institute (Bethesda, USA). Gentamicin
(50mg gentamicin sulfate/mL), L-glutamine (200mM), and
fetal calf serum were from Invitrogen (Mulgrave, Australia).
The Annexin V-PE Apoptosis Detection Kit I was from BD
Pharmingen (North Ryde, Australia).
2.2. Cell Lines and Their Culture. MEC2 cells (derived from
a B-cell CLL) were a kind of gift from Dr. Federico Caligaris-
Cappio, (University of Torino, Italy; [21]). Raji cells (from
a B-cell Burkitt’s lymphoma) were from the American Type
Culture Collection (Manassas, USA; [22]). MEC2 and Raji
cells were grown in Hepes-buﬀered RPMI 1640 medium
with 10% (v/v) fetal calf serum, 50μg/mL gentamicin, and
2mM L-glutamine at 37
◦C in a nonhumidiﬁed atmosphere
without CO2. Cultures of MEC2 and Raji at a density of 3 ×
105 cells/mL were treated with CdA or FdA (1μM, 24 hours)
and harvested for surface proﬁling of CD antigens.
2.3. Apoptosis Detection. Externalization of phosphatidylser-
ine (PS) on cells during apoptosis was quantiﬁed by Annexin
V-PE binding, while the loss of cell membrane integrity indi-
cating dead cells was demonstrated by binding of 7-amino-
actinomycin D (7-AAD) to DNA. Brieﬂy, cells were washed
twice with PBS and resuspended at a density of 106 cells/mL
in binding buﬀer (10mM Hepes pH 7.4, 140mM NaCl,
and 2.5mM CaCl2). An aliquot of the suspension (50μL,
0.5 × 105 cells) was incubated with 2.5μL of Annexin V-PE
and 2.5μL of 7-AAD for 15 minutes at room temperature.
Cells were then resuspended in 450μL of binding buﬀer
and analyzed with an FACScan ﬂow cytometer (Becton
Dickinson, San Jose, USA) using CellQuest software.
2.4. Proﬁling of Cells on CD Antibody Microarrays.
DotScanTM microarrays were obtained from Medsaic
(Eveleigh,Australia).Captureofcellson82-dotCDantibody
microarrays, imaging, and data analysis have been described
[23]. Dot patterns of cells captured on CD antibody
microarrays were imaged and analyzed using a scanner and
software from Medsaic [23]. Data were normalized to a
maximum 8-bit dot intensity value of 256. Experiments
to determine the eﬀects of CdA or FdA (1μM, 24 hours)
on the immunophenotypes of cells were performed in
triplicate. For each cell line, three cell cultures were treated
with CdA or FdA dissolved in dimethylformamide, while the
three control cultures were treated with the corresponding
amount of dimethylformamide. Data are expressed as means
with standard errors.
2.5. Flow Cytometry of Cells. CD antigens whose levels
changed on Raji and MEC2 cells using DotScanTM were also
analyzedquantitativelybyﬂowcytometryusingFITC-orPE-
conjugated monoclonal antibodies and standard procedures.
Fluorescently-labelled monoclonal antibodies were obtained
from Becton-Dickinson Pharmingen (North Ryde, Aus-
tralia), IMM, Immunotech, Beckman Coulter (Gladesville,
Australia), and CALTAG, Invitrogen (Mount Waverley, Aus-
tralia). Samples were analyzed using an FACScalibur ﬂow
cytometer (Becton Dickinson, San Jose, USA) with a 488-nm
air-cooled argon-ion laser, running CellQuest Pro software.
Fluorescence detection used logarithmic ampliﬁcation (FL1
(green) = 530/30nm; FL2 (red) = 585/40nm). Quantitative
data are the averages of 3 determinations with variance
expressed as P-values.
3. Results
3.1. Eﬀects of Purine Analogs on Cell Growth and Viability.
Cell viability was assessed by Trypan blue exclusion. CdA
(1μM) arrested growth of Raji and MEC2 cells, and FdA
(1μM) arrested Raji cells but not MEC2 cells (data not
shown). Apoptotic and dead cells were quantiﬁed using
Annexin V-PE and 7-AAD with ﬂow cytometry (Figure 1).
CdA (1μM, 24 hours) induced for Raji: apoptosis (control
8.4%, + CdA 36.3%) and cell death (control 9.5%, + CdA
12.3%), for MEC2 cells: apoptosis (control 7.5%, + CdA
23%) and cell death (control 3.4%, + CdA 6.7%). FdA
(1μM, 24 hours) induced for Raji: apoptosis (control 8.4%,
+ FdA 21.2%) and cell death (control 9.5%, + FdA 9.8%).
FdA (1μM, 24 hours) had no signiﬁcant eﬀect on MEC2:
apoptosis (control 7.5%, + FdA 10%) and cell death (control
3.4%, + FdA 4.1%).
3.2. Eﬀects of Purine Analogs on Cell Surface Proﬁles Using
Microarrays. CD antibody microarrays were used to screen
for immunophenotypic changes on Raji and MEC2 cells
induced by CdA or FdA (1μM, 24 hours). The expression
proﬁles in Figure 2 show mean cell binding densities from
analysis of control and drug-treated cultures (n = 3). For Raji
cells, CdA (1μM, 24 hours) increased levels of CD54, CD80,
CD86, and CD95, while CD22 was repressed (Figure 2(a)).International Journal of Proteomics 3
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Figure 1: Induction of apoptosis of Raji and MEC2 cells by purine analogs. Samples of cells were taken at the indicated times, stained with
Annexin V-PE and 7-AAD, and analyzed by ﬂow cytometry as described in Materials and Methods. (a) Control, (b) CdA (1μM, 24 hours),
and (c) FdA (1μM, 24 hours).
FdA (1μM, 24 hours) increased levels of CD20 (rituximab),
CD54, CD80, CD86, and CD95 (Figure 2(b)). Although
an increase in CD20 was observed with two other clones
of CD20 antibody (B1, B9E9), these changes were not
signiﬁcant (P>. 05). For MEC2 cells, CdA increased CD20
(B9E9),CD45,CD62L, CD80,CD86, CD95,whileCD54was
repressed (Figure 2(c)). The changes for MEC2 with CdA
wereconsistent,butonlyCD86up-regulationwassigniﬁcant
(P<. 05). DotScanTM microarrays provide extensive surface
proﬁles of CD antigens that are semiquantitative. Flow
cytometry was used to conﬁrm and quantify levels of CD
antigens.
3.3. Eﬀects of Purine Analogs on Surface Antigens Using Flow
Cytometry. For conﬁrmation, MEC2 and Raji cells were
treated with CdA or FdA (1μM, 24 hours), and CD antigens
of interest were analyzed by ﬂow cytometry. CellQuest Pro
software (Becton Dickinson, San Jose, USA) was used to
overlay the ﬂuorescence histograms and obtain the median
ﬂuorescence intensities for calculation of the fold-changes
of CD antigen expression (drug-treated)/(control). Figure 3
shows overlays of ﬂuorescence histograms of control (grey)
and drug-treated (black outline) samples. These results
conﬁrm that CdA (1μM, 24 hours) induced increases on
Raji cells of CD54, CD80, CD86, and CD95, and CD22 was
decreased (Figure 3(a)). In addition, increased CD10 was
detected on Raji cells treated with CdA. Raji cells treated
with FdA (1μM, 24 hours) showed increased CD20, CD54,
CD80, CD86, and CD95 (Figure 3(b)). MEC2 cells treated
with CdA (1 μM, 24 hours) showed increased CD20, CD45,
CD62L, CD80, CD86, and CD95. Increased CD11a, CD43,
CD52, and CD54 were also detected by ﬂow cytometry but
not microarrays. No changes in CD antigen expression were
observed for MEC2 cells treated with FdA (data not shown).
Table 1 summarizes the ﬂow cytometric data for Raji and
MEC2 cells treated with these purine analogs (Figure 3).
4. Discussion
CdA and FdAMP are eﬀective for treatment of CLL and low-
grade NHL [24]. Recent studies indicate that purine analogs
administered in combination with other drugs and/or
therapeutic antibodies (rituximab and alemtuzumab) may
producehigherresponseratesincludingcompleteremissions
[25]. Proteomic analysis of Raji cells treated with FdA using
two-dimensional gel electrophoresis and mass spectrometry
has identiﬁed new nuclear regulatory proteins that may
participate in FdA-induced apoptosis. Analysis of cytosolic4 International Journal of Proteomics
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Figure 2: Expression of CD antigens on Raji and MEC2 cells treated with purine analogs (1μM, 24 hours) analyzed using microarrays. (a)
Raji + CdA, (b) Raji + FdA, and (c) MEC2 + CdA. Expression proﬁles were generated from the dot patterns of cells captured on microarrays;
control (grey bars), drug-treated (black bars). CD antigens are labelled on the abscissa, average dot intensities on an 8-bit greyness scale
(1–256) on the ordinate. Mean dot intensities are plotted with standard error bars (n = 3). Asterisks indicate signiﬁcant (P<. 05) changes.
and mitochondrial proteins has identiﬁed 25 proteins that
diﬀer by more than 2-fold between control cultures and
purine analog-treated Raji cells (Mactier, Henrich, and
Christopherson,manuscriptsubmitted).Theseproteinspro-
vide further insight into the mechanisms of action of purine
analogsandmayrepresentnewtherapeutictargets.Antibody
microarray-based technology is a promising tool in the ﬁeld
of proteomics, in which one of the important applications
is to compare proteomic proﬁles of untreated and drug-
treated cancer cells to identify potential drug targets as well
as further elucidate mechanisms of drug treatment. In the
present study, DotScanTM a n ti bo d ym i c r oa rra y sw e r eu s e dt oInternational Journal of Proteomics 5
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Figure 3: Expression of CD antigens on Raji and MEC2 cells treated with purine analogs (1μM, 24 hours) analyzed using ﬂow cytometry.
(a) Raji + CdA, (b) Raji + FdA, and (c) MEC2 + CdA. Raji and MEC2 cells were exposed to CdA or FdA (1μM, 24 hours), incubated with
FITC- or PE-conjugated antibodies against CD antigens, and analyzed by ﬂow cytometry. The grey area represents untreated cells; the black
outline is cells exposed to a purine analog. The ﬁgures are representative of 3 technical replicates. A shift in the median ﬂuorescence intensity
indicates up- or down-regulation of an antigen. Diﬀerential abundances of these CD antigens are quantiﬁed in Table 1.
screen for changes induced by purine analogs on the surface
of leukemia and lymphoma cell lines. CdA and FdA induced
up-regulation of a number of CD antigens on MEC2 and
Raji cells that could be targets for synergistic treatment with
therapeutic antibodies.
CD10, a neutral endopeptidase and integral membrane
protein whose expression correlates with apoptosis [26,
27], was induced 2.4-fold on Raji cells treated with CdA
(Table 1). CD54 (intercellular adhesion molecule-1, ICAM-
1), a member of the immunoglobulin superfamily of
adhesion molecules, was up-regulated 1.4- to 1.8-fold on
Raji cells treated with CdA or FdA and on MEC2 cells
treated with CdA (Table 1). CD11a (lymphocyte function-
associated antigen 1, LFA-1 integrin) increased 1.4-fold
on MEC2 cells treated with CdA (Table 1). When T cells
encounter antigen-presenting cells (APCs), cell-cell con-
tact is established between LFA-1 (CD11a) and ICAM-1
(CD54). CD20 was induced 1.6-fold on MEC2 cells treated
with CdA and 1.5-fold on Raji cells treated with FdA
(Table 1). CD20, a B-cell antigen, is a calcium channel that
regulates cell-cycle progression and proliferation. CD20 is
expressed at lower levels on B-CLL compared with normal
B-cells and other B-LPD [28]. Van Meerten et al. [29]
showed that increased CD20 enhances antibody-dependent
cellular cytotoxicity (ADCC) and complement dependent
cytotoxicity (CDC). Combination therapy using CdA or
FdAMP with rituximab is clinically synergistic against CLL
and lymphomas [18, 30, 31]. The up-regulation of CD20
observed (Table 1) may provide an explanation for this
synergy.6 International Journal of Proteomics
Table 1: Diﬀerential abundance of CD antigens on Raji and MEC2 cells after treatment with CdA or FdA assessed by ﬂow cytometry.
Raji + CdA Raji + FdA MEC2 + CdA
CD antigen Fold change1 P-value2 Fold change P-value Fold change P-value
CD10 2.4 1 ×10
−3 No change No change
CD11a n.d. n.d. 1.4 1.6 × 10
−4
CD20 No change 1.5 6.5 ×10
−2 1.6 2 ×10
−6
CD22 0.51 2 ×10
−6 No change No change
CD43 n.d. n.d. 1.5 1 ×10
−5
CD45 n.d. n.d. 1.3 1.6 × 10
−2
CD52 No change No change 1.6 2.6 × 10
−3
CD54 1.7 7 ×10
−4 1.8 1.7 ×10
−2 1.4 4 ×10
−3
CD62L n.d. n.d. 2.0 3 ×10
−6
CD80 1.5 1 ×10
−3 1.5 5 ×10
−5 1.5 2 ×10
−5
CD86 1.9 3 ×10
−5 1.4 1.2 ×10
−4 2.5 1 ×10
−4
CD95 1.2 8 ×10
−5 1.4 1.1 ×10
−4 1.5 2.8 × 10
−3
1Fold change calculated by dividing the median ﬂuorescence intensity for the drug-treated sample by that for the control (Figure 3).
2P-value calculated using the students’ t-test (n = 3).
n.d.: CD antigen not detected.
CD22, a regulator of the B-cell receptor (BCR),
was repressed 0.51-fold on Raji cells treated with CdA
(Table 1). CD22 is a B-cell-speciﬁc sialoglycoprotein of
the immunoglobulin superfamily commonly expressed on
NHL [32] involved with cellular adhesion and homing
and regulation of B-cell activation. Monoclonal antibodies
against CD22 that block ligand binding inhibit normal and
malignant B-cell survival [33]. Repression of CD22 on Raji
cells by CdA may reduce CD22 signaling, decrease pro-
liferation, and promote apoptosis. CD43 was up-regulated
1.5-fold on MEC2 cells treated with CdA (Table 1). CD43
participates in signaling and activation of T lymphocytes
[34]. Overexpression of CD43 induces accumulation of p53
[35], while monoclonal antibodies binding to CD43 may
induce apoptosis [36–38].
CdA induced CD52 1.6-fold on MEC2 cells (Table 1).
Alemtuzumab (Campath-1H), a therapeutic antibody
against CD52, induces CDC and ADCC and is eﬀective for
treatment of CLL [25]. It was shown that alemtuzumab
in combination with a purine nucleoside analog may be
eﬀective for treatment of refractory CLL [17]. CD62L
(L-selectin, LECAM-1) is up-regulated 2-fold on MEC2
cells treated with CdA (Table 1). The expression of adhesion
molecules may alter the mobility and homing of CLL
cells and the immune response to CLL. The level of
CD62L on B-CLL is usually less than half that of normal
lymphocytes, possibly contributing to accumulation of
B-CLL in peripheral blood [39].
CD80 and CD86 are up-regulated 1.4- to 2.5-fold on
Raji and MEC2 cells treated with CdA or FdA (Table 1).
These coregulators of T cell activation induce proliferation,
cytokine production, and eﬀector functions. Up-regulation
of CD80 and CD86 may enhance a T cell response to
CLL and lymphoma [40]. CD80 may also play a role in
regulation of normal and malignant B-cells [41]a n dm a y
be constitutively expressed on NHL, making it an attractive
targetforlymphomatherapy[42].Galiximabisatherapeutic
antibody directed against CD80 that has been used to treat
NHL [11, 43]. CD95 is up-regulated 1.2- to 1.5-fold on Raji
and MEC2 cells treated with CdA or FdA (Table 1). The
Fas (CD95)/Fas ligand (CD178) system has a potential role
in cytotoxic killing of some leukemias [44]. CdA-induced
apoptosis may be triggered by the expression of Fas and Fas-
L[ 45], and FdA induces Fas and Fas-L mRNAs [46]. The
enhanced expression of CD95 on CLL cells treated with CdA
or FdA could promote cell killing.
While CdA and FdA are structurally similar, there
are some diﬀerences in their eﬀects. In this study, CdA
induced immunophenotypic changes and apoptosis in the
CLL-derived cell line MEC2 that is resistant to FdA. A
recent clinical trial showed prolongation of therapeutic
responsewithCdAcomparedtoFdAMP[47]suggestingthat
CdA should be further investigated for treatment of CLL.
Surface molecules up-regulated by a purine analog could
be targeted with a therapeutic antibody providing synergy
and more eﬀective treatment. Our results may explain the
clinical synergy between FdA and rituximab. CdA and FdA
upregulate CD antigens on Raji and MEC2 cells that are
targets for therapeutic antibodies such as rituximab (anti-
CD20), alemtuzumab (anti-CD52), and galiximab (anti-
CD80).CD10,CD11a,CD43, CD54,CD62L,andCD86, also
up-regulated by FdA or CdA (Figures 2 and 3, Table 1), are
potential targets for development of therapeutic antibodies,
for drug-antibody combination therapy. Preliminary experi-
mentswithprimarycellsfromCLLpatientsshowedthatCdA
or FdA (1μM, 48 hours) induces increases in CD20, CD54,
and CD95 (not shown).
Insummary,microarrayanalysisofRajicellstreatedwith
purine analogs revealed signiﬁcant changes (P<. 05) in
expression levels of several cell surface antigens, that were
conﬁrmedbyﬂowcytometry(Figures2and 3,Table 1).Flow
cytometry also revealed signiﬁcant CdA-induced increases
in cell surface antigens on MEC2 cells (P<. 05, Figure 3,
Table 1) ,b u tn o ta l lo ft h e s ec h a n g e sw e r es i g n i ﬁ c a n tb yInternational Journal of Proteomics 7
microarray although the same antibody clones were used.
The diﬀerences between microarray and ﬂow cytometry
results for CdA-treated MEC2 cells are not fully understood.
Flow cytometry uses soluble ﬂuorescent antibodies, which
have greater ﬂexibility and freedom of movement than anti-
bodies immobilized on a nitrocellulose surface and therefore
have easier access to cell surface antigens, with ﬂuorescence
intensity directly reﬂecting antigen expression levels. Cell
viability is not essential for ﬂow cytometry, while cell capture
on antibody dots depends not only on the interaction
of cell surface antigens with immobilized antibodies but
also on energy-dependent processes required for robust
attachment of antibody-bound cells to the nitrocellulose
s u r f a c e ;d a m a g e do rd e a dc e l l sb i n dw e a k l ya n da r ee a s i l y
washed oﬀ during washing and ﬁxation steps. The tendency
of MEC2 cells to cluster rapidly in suspension may, at
least in part, account for greater variability in replicate dot
intensities for MEC2 compared to Raji (Figure 2(c) versus
2(a)), because cell clusters are less ﬁrmly bound to antibody
dots than single cells due to reduced interaction of clustered
cells with the immobilized antibodies.
DotScanTM microarrays provide a powerful screening
tool for the detection of drug-induced modulations of
cell surface antigens and could be used to screen patient
samples to identify other potential synergistic drug-antibody
combinations for CLL and other B-LPDs. Microarray-based
proteomic analysis should also enable rational development
of chemoimmunotherapy for less common disease entities
and subsets and enable tailored treatment for individual
patients.
Abbreviations
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FdA: Fludarabine nucleoside
FdAMP: Fludarabine.
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